Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Adcirca Tadalafil Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Do not list Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Withdrawn
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder, Adult Do not list Complete
Adempas Riociguat Chronic thromboembolic pulmonary hypertension List with criteria/condition Complete
Adempas Riociguat Pulmonary arterial hypertension (WHO group 1) List with clinical criteria and/or conditions Complete
Adlyxine lixisenatide Diabetes mellitus, Type 2 Reimburse with clinical criteria and/or conditions Complete
Admelog Insulin lispro Cancelled
Adtralza tralokinumab atopic dermatitis Do not reimburse Complete
Adtralza tralokinumab atopic dermatitis (AD) Do not reimburse Active
Aduhelm aducanumab Alzheimer’s disease Withdrawn
Advicor Niacin/lovastatin Hypercholesterolemia and mixed dyslipidemia List Complete
Aermony RespiClick fluticasone propionate Asthma Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) Do not list Complete
Afinitor Everolimus Subependymal giant cell astrocytoma associated with tuberous sclerosis complex Do not list Complete
Afinitor Everolimus Pancreatic Neuroendocrine Tumour Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Advanced Breast Cancer Reimburse with clinical criteria and/or conditions Complete
Afinitor Everolimus Neuroendocrine tumors (NET) of Gastrointestinal or Lung origin Reimburse with clinical criteria and/or conditions Complete
Aimovig erenumab Migraine Reimburse with clinical criteria and/or conditions Complete
Ajovy fremanezumab migraine Reimburse with clinical criteria and/or conditions Complete
Akeega niraparib abiraterone acetate Metastatic castration-resistant prostate cancer (mCRPC) Reimburse with clinical criteria and/or conditions Complete
Akynzeo netupitant / palonosetron Nausea and vomiting (chemotherapy induced) prevention Reimburse with clinical criteria and/or conditions Complete
Albrioza sodium phenylbutyrate and ursodoxicoltaurine Amyotrophic lateral sclerosis (ALS) Reimburse with clinical criteria and/or conditions Complete
Aldurazyme Laronidase Mucopolysarccharidosis 1 (MPS 1), Hurler, Hurler-Scheie, Scheie Do not list Complete
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete